Evidence map›Paper›PMID 34983515›Full record

ArticleRespiratory research2022

IgE is associated with exacerbations and lung function decline in COPD.

Marek Lommatzsch, Timotheus Speer, Christian Herr, Rudolf A Jörres, Henrik Watz, Achim Müller, Tobias Welte, Claus F Vogelmeier, Robert Bals, COSYCONET study group

Registry-linked trialOpen access · goldAbstract readMulticenter Study
In one paragraph

Article in Respiratory research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01245933 (Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD), which is not on this map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01245933 completednot on this map

Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD

TypeobservationalSponsorPhilipps University MarburgRan2010 to 2023Enrolled2,741ConditionsChronic Obstructive Pulmonary Disease (COPD)
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 46 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Polymorphisms in theJournal of thoracic disease · 2023
    Article
  14. Article
  15. Review
  16. The Acari Hypothesis, III: Atopic Dermatitis.Pathogens (Basel, Switzerland) · 2022
    Article
  17. Pollen Exposure and Cardiopulmonary Health Impacts in Adelaide, South Australia.International journal of environmental research and public health · 2022
    Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Marek LommatzschUniversity of Rostock, Rostock, Germany.ORCID http://orcid.org/0000-0002-9305-9348
Timotheus SpeerDepartment of Internal Medicine IV, Nephrology, Saarland University Hospital, Homburg, Germany.
Christian HerrDepartment of Internal Medicine V - Pulmonology, Allergology, Critical Care Medicine, Saarland University Medical Center, 66421, Homburg, Germany.
Rudolf A JörresUniversity of Munich, Munich, Germany.
Henrik WatzAirway Research Center North (ARCN), German Center for Lung Research (DZL), Pulmonary Research Institute at LungenClinic Grosshansdorf, Grosshansdorf, Germany.
Achim MüllerBoehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany.
Tobias WelteGerman Center for Lung Research (DZL), University of Hannover, Hannover, Germany.
Claus F VogelmeierGerman Center for Lung Research (DZL), Department of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-Universität Marburg, Marburg, Germany.
Robert BalsDepartment of Internal Medicine V - Pulmonology, Allergology, Critical Care Medicine, Saarland University Medical Center, 66421, Homburg, Germany. robert.bals@uks.eu.ORCID http://orcid.org/0000-0002-1472-9535
COSYCONET study group
Saarland University · DEGerman Center for Lung Research · DEBoehringer Ingelheim (Germany) · DELudwig-Maximilians-Universität München · DEPhilipps University of Marburg · DEUniversity of Rostock · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBoth allergen-specific IgE and total IgE in serum play a major role in asthma. However, the role of IgE in chronic obstructive pulmonary disease (COPD) is poorly understood. It was the aim of this study to systematically analyze the relationship between serum IgE levels and disease characteristics in large COPD cohorts.

methodsCOSYCONET is a comprehensively characterized cohort of patients with COPD: total IgE and IgE specific to common aeroallergens were measured in serum of 2280 patients, and related to clinical characteristics of the patients. WISDOM is another large COPD population (2477 patients): this database contains the information whether total IgE in serum was elevated (≥ 100 IU/l) or normal in patients with COPD.

resultsBoth in COSYCONET and WISDOM, total IgE was elevated (≥ 100 IU/l) in > 30% of the patients, higher in men than in women, and higher in currently than in not currently smoking men. In COSYCONET, total IgE was elevated in patients with a history of asthma and/or allergies. Men with at least one exacerbation in the last 12 months (50.6% of all men in COSYCONET) had higher median total IgE (71.3 IU/l) than men without exacerbations (48.3 IU/l): this difference was also observed in the subgroups of not currently smoking men and of men without a history of asthma. Surprisingly, a history of exacerbations did not impact on total IgE in women with COPD. Patients in the highest tertiles of total IgE (> 91.5 IU/ml, adjusted OR: 1.62, 95% CI 1.12-2.34) or allergen-specific IgE (> 0.19 IU/ml, adjusted OR: 2.15, 95% CI 1.32-3.51) were at risk of lung function decline (adjusted by: age, gender, body mass index, initial lung function, smoking status, history of asthma, history of allergy).

conclusionThese data suggest that IgE may play a role in specific COPD subgroups. Clinical trials using antibodies targeting the IgE pathway (such as omalizumab), especially in men with recurrent exacerbations and elevated serum IgE, could elucidate potential therapeutic implications of our observations.

Indexed as

AgedBiomarkersDisease ProgressionFemaleFollow-Up StudiesHumansImmunoglobulin ELungMaleMiddle AgedPulmonary Disease, Chronic ObstructiveRespiratory Function TestsRetrospective StudiesBiomarkersImmunoglobulin ECOPDExacerbationsIgELung function decline

Identifiers

PMID34983515
PMCPMC8725269
OpenAlexW4205283895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.